Payment overview · 2025
General Payments
$812.23
56 reported records · 10 companies
Healthcare provider profile · identity verified
Vernon Eugene Taylor, APRN
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · GRAY, KY · NPI 1326380304
Verified facts
What the public records show
CMS Open Payments records show Vernon Eugene Taylor, APRN received $812.23 in general payments during 2025 across 56 reported records.
Lilly USA, LLC accounted for 18.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 111 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $149.31 | 18.4% | 11 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $144.83 | 17.8% | 6 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $140.43 | 17.3% | 15 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $138.14 | 17.0% | 9 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $96.79 | 11.9% | 6 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $64.41 | 7.9% | 4 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $28.53 | 3.5% | 2 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.90 | 2.6% | 1 | 2025 |
| Indivior Inc. | Unresolved — no canonical attribution shown | $15.31 | 1.9% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $13.58 | 1.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $812.23 | 56 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $138.14 | 9 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $108.58 | 12 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $95.29 | 11 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $80.34 | 7 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $80.34 | 7 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $68.97 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $50.55 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $50.55 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $46.24 | 3 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $34.39 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $31.85 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $30.02 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $30.02 | 2 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $28.53 | 2 | 2025 |
Source payment records
|
|||||
| HETLIOZ Normalized: hetlioz |
Drug | Vanda Pharmaceuticals Inc. | $28.53 | 2 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $20.90 | 1 | 2025 |
Source payment records
|
|||||
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $15.31 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $13.58 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $13.58 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 28 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 111 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 67 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
22 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
43 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
28 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
111 | 31 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
44 | 17 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
67 | 20 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
36 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 309 | 103 |
| Gabapentin | Gabapentin | 288 | 67 |
| Amlodipine Besylate | Amlodipine Besylate | 202 | 75 |
| Atorvastatin Calcium | Atorvastatin Calcium | 192 | 72 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 164 | 47 |
| Lisinopril | Lisinopril | 154 | 55 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 152 | 63 |
| Methylprednisolone | Methylprednisolone | 149 | 108 |
| Omeprazole | Omeprazole | 149 | 52 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 148 | 27 |
| Pantoprazole Sodium | Pantoprazole Sodium | 131 | 58 |
| Tamsulosin Hcl | Tamsulosin Hcl | 123 | 43 |
| Losartan Potassium | Losartan Potassium | 121 | 46 |
| Fluticasone Propionate | Fluticasone Propionate | 112 | 41 |
| Mounjaro | Tirzepatide | 111 | 31 |
| Famotidine | Famotidine | 109 | 39 |
| Metformin Hcl | Metformin Hcl | 91 | 34 |
| Tramadol Hcl | Tramadol Hcl | 83 | 25 |
| Metoprolol Succinate | Metoprolol Succinate | 82 | 31 |
| Ondansetron Odt | Ondansetron | 82 | 32 |
| Furosemide | Furosemide | 80 | 34 |
| Tizanidine Hcl | Tizanidine Hcl | 75 | 27 |
| Metoprolol Tartrate | Metoprolol Tartrate | 74 | 29 |
| Ibuprofen | Ibuprofen | 70 | 25 |
| Alprazolam | Alprazolam | 69 | 13 |
| Levofloxacin | Levofloxacin | 67 | 52 |
| Ozempic | Semaglutide | 67 | 20 |
| Pregabalin | Pregabalin | 67 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 64 | 32 |
| Atenolol | Atenolol | 61 | 19 |
| Montelukast Sodium | Montelukast Sodium | 58 | 23 |
| Zolpidem Tartrate | Zolpidem Tartrate | 58 | 15 |
| Prednisone | Prednisone | 57 | 30 |
| Promethazine Hcl | Promethazine Hcl | 57 | 17 |
| Azithromycin | Azithromycin | 56 | 45 |
| Diclofenac Sodium | Diclofenac Sodium | 56 | 19 |
| Fluconazole | Fluconazole | 56 | 35 |
| Ventolin Hfa | Albuterol Sulfate | 56 | 19 |
| Glipizide | Glipizide | 55 | 17 |
| Carvedilol | Carvedilol | 54 | 16 |
| Clonazepam | Clonazepam | 54 | 14 |
| Sertraline Hcl | Sertraline Hcl | 52 | 19 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 51 | 19 |
| Meloxicam | Meloxicam | 51 | 24 |
| Clopidogrel | Clopidogrel Bisulfate | 50 | 18 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 48 | 17 |
| Escitalopram Oxalate | Escitalopram Oxalate | 47 | 16 |
| Buspirone Hcl | Buspirone Hcl | 46 | 21 |
| Allopurinol | Allopurinol | 45 | 19 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 45 | 17 |
| Trulicity | Dulaglutide | 44 | 17 |
| Farxiga | Dapagliflozin Propanediol | 43 | 12 |
| Mirtazapine | Mirtazapine | 43 | 21 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 42 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 42 | 14 |
| Simvastatin | Simvastatin | 42 | 15 |
| Baclofen | Baclofen | 41 | 18 |
| Mupirocin | Mupirocin | 41 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 40 | 16 |
| Lorazepam | Lorazepam | 40 | 11 |
| Potassium Chloride | Potassium Chloride | 40 | 17 |
| Hydrochlorothiazide | Hydrochlorothiazide | 39 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 39 | 13 |
| Alendronate Sodium | Alendronate Sodium | 38 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 37 | 14 |
| Eliquis | Apixaban | 36 | 13 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 35 | 32 |
| Repatha Sureclick | Evolocumab | 35 | suppressed |
| Celecoxib | Celecoxib | 34 | 13 |
| Finasteride | Finasteride | 34 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 34 | 17 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 33 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 33 | 14 |
| Testosterone Cypionate | Testosterone Cypionate | 33 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 32 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 32 | 13 |
| Spironolactone | Spironolactone | 32 | 14 |
| Donepezil Hcl | Donepezil Hcl | 31 | 14 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 31 | 27 |
| Bupropion Xl | Bupropion Hcl | 29 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 29 | 12 |
| Jardiance | Empagliflozin | 28 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 28 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 28 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 27 | 18 |
| Ezetimibe | Ezetimibe | 27 | suppressed |
| Fenofibrate | Fenofibrate | 27 | suppressed |
| Linzess | Linaclotide | 27 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 25 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 25 | 15 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 25 | suppressed |
| Clonidine | Clonidine | 24 | suppressed |
| Lansoprazole | Lansoprazole | 24 | suppressed |
| Valsartan | Valsartan | 24 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 23 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 23 | suppressed |
| Metronidazole | Metronidazole | 22 | suppressed |
| Synthroid | Levothyroxine Sodium | 22 | 11 |
| Glipizide Er | Glipizide | 21 | suppressed |
| Nystatin | Nystatin | 21 | 11 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 20 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 20 | 20 |
| Amitriptyline Hcl | Amitriptyline Hcl | 19 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 19 | suppressed |
| Vascepa | Icosapent Ethyl | 19 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 18 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 18 | 12 |
| Trazodone Hcl | Trazodone Hcl | 18 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 17 | suppressed |
| Topiramate | Topiramate | 17 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 16 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 16 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 15 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 15 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 15 | suppressed |
| Bumetanide | Bumetanide | 14 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 14 | suppressed |
| Loperamide | Loperamide Hcl | 14 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 14 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 14 | suppressed |
| Amoxicillin | Amoxicillin | 13 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 13 | suppressed |
| Levemir Flexpen | Insulin Detemir | 13 | suppressed |
| Rexulti | Brexpiprazole | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 12 | suppressed |
| Diazepam | Diazepam | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Glimepiride | Glimepiride | 12 | suppressed |
| Methotrexate | Methotrexate Sodium | 12 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 12 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 11 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 11 | suppressed |
| Temazepam | Temazepam | 11 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $812.23 · 56 records | Lilly USA, LLC | EVENITY, FANAPT, GVOKE HYPOPEN, HETLIOZ, JARDIANCE, Kerendia, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, PAXLOVID, QULIPTA, REPATHA, Rybelsus, SUBLOCADE, UBRELVY, VRAYLAR, Wegovy, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error